Skip to main content

Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies

Abstract: Efficacy exposure–response relationships of the CCR5 antagonist maraviroc were evaluated across two phase III clinical trials. This post-hoc analysis used 48-week efficacy data from 841 treatment-experienced patients infected with CCR5-tropic human immunodeficiency virus type 1 (HIV-1), identified by the enhanced sensitivity Trofile assay. Probability of treatment success (viral RNA

Full Reference: Jacqmin, P., J. R. Wade, B. Weatherley, E. Snoeck, S. Marshall, and L. McFadyen. “Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.” CPT: Pharmacometrics & Systems Pharmacology 2 (August 14, 2013): e64. doi:10.1038/psp.2013.42.

Link to full text:

How can we help you?